Esperion Therapeutics (ESPR) News Today → Like Tiny Crypto Retirement Funds (From Crypto 101 Media) (Ad) Free ESPR Stock Alerts $2.05 -0.02 (-0.97%) (As of 03/18/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineTerns to report Phase 1 data on GLP-1 drug in 2H 2024msn.com - March 14 at 8:52 PMGSA Capital Partners LLP Has $1.09 Million Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)marketbeat.com - March 10 at 7:48 AM11 Best Small Cap Pharma Stocks to Invest Infinance.yahoo.com - March 4 at 9:04 PMEsperion Therapeutics, Inc. Expected to Earn Q1 2024 Earnings of ($0.24) Per Share (NASDAQ:ESPR)marketbeat.com - March 2 at 2:29 AMEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Rating of "Hold" by Analystsmarketbeat.com - March 1 at 1:26 AMA Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeuticsseekingalpha.com - February 28 at 7:10 PMEsperion Therapeutics (NASDAQ:ESPR) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPSmarketbeat.com - February 28 at 10:27 AMEsperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 28 at 9:09 AMQ4 2023 Esperion Therapeutics Inc Earnings Callfinance.yahoo.com - February 28 at 12:41 AMEsperion Therapeutics, Inc.: Esperion Reports Fourth Quarter and Full Year 2023 Financial Resultsfinanznachrichten.de - February 27 at 9:40 AMEsperion Therapeutics Inc (ESPR) Reports Strong Revenue Growth in Q4 and FY 2023finance.yahoo.com - February 27 at 9:40 AMEsperion Reports Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - February 27 at 6:00 AM12 Best Medical Stocks to Buy Under $10finance.yahoo.com - February 27 at 4:40 AMEarnings Preview: Esperion Therapeuticsbenzinga.com - February 26 at 10:39 PMEsperion Therapeutics, Inc.edition.cnn.com - February 26 at 5:39 PMWhat Wall Street expects from Esperion Therapeutics's earningsmarkets.businessinsider.com - February 26 at 12:39 PMEsperion Therapeutics Q4 2023 Earnings Previewmsn.com - February 26 at 12:39 PMESPR Jan 2026 4.000 callca.finance.yahoo.com - February 19 at 1:42 AMESPR Jan 2026 1.000 callca.finance.yahoo.com - February 18 at 8:42 PMESPR Jan 2026 1.000 putca.finance.yahoo.com - February 18 at 3:41 PMESPR Jan 2026 3.000 callca.finance.yahoo.com - February 18 at 3:41 PMESPR Mar 2024 2.500 putfinance.yahoo.com - February 18 at 3:41 PMESPR Mar 2024 6.000 callfinance.yahoo.com - February 16 at 10:30 PMEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)finance.yahoo.com - February 16 at 5:30 PMEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)globenewswire.com - February 16 at 4:30 PMShould You Sell Esperion Therapeutics (ESPR)?finance.yahoo.com - February 15 at 9:39 AMEsperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27finance.yahoo.com - February 13 at 8:16 AMEsperion Therapeutics, Inc. (ESPR)uk.finance.yahoo.com - February 6 at 2:39 PMQ1 2024 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Boosted by Zacks Researchmarketbeat.com - February 5 at 1:41 AMEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Rating of "Moderate Buy" by Analystsmarketbeat.com - February 5 at 1:26 AMRFK, Esperion Therapeutics Announce 2024 Promotional Schedulefinance.yahoo.com - February 1 at 7:04 PMPeering Into Esperion Therapeutics's Recent Short Interestbenzinga.com - January 31 at 2:37 PMEsperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Sharesfinance.yahoo.com - January 23 at 8:50 PMEsperion Therapeutics Shares Tumble Premarket on Stock Offeringmarketwatch.com - January 19 at 6:23 PMWhy Is Esperion Therapeutics (ESPR) Stock Down 24% Today?investorplace.com - January 19 at 9:15 AMEsperion Therapeutics Prices Public Offering Of 56.70 Mln Shares At $1.50/shr; Stock Plungesmarkets.businessinsider.com - January 19 at 8:22 AMEsperion Therapeutics stock slides on pricing stock offering to raise $85.1 millionmsn.com - January 19 at 8:22 AMEsperion Announces Pricing of $85.1 Million Public Offering of Common Stockfinance.yahoo.com - January 19 at 12:51 AMEsperion Announces Proposed Public Offering of Common Stockfinance.yahoo.com - January 18 at 7:50 PMShort Interest in Esperion Therapeutics, Inc. (NASDAQ:ESPR) Increases By 9.2%marketbeat.com - January 15 at 7:57 AMEsperion Is Sitting On A Potential Blockbuster Drugseekingalpha.com - January 14 at 1:45 PMMeditor Group Ltd Cuts Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)marketbeat.com - January 14 at 10:25 AMEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Hold" from Analystsmarketbeat.com - January 11 at 2:21 AMResearch Analysts Set Expectations for Esperion Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:ESPR)marketbeat.com - January 5 at 7:47 AMEsperion Therapeutics (NASDAQ:ESPR) Stock Rating Lowered by Bank of Americamarketbeat.com - January 3 at 1:16 PMEsperion Therapeutics Sees Unusually Large Options Volume (NASDAQ:ESPR)marketbeat.com - January 3 at 11:35 AMEsperion Therapeutics, Daiichi Sankyo Europe Ink $125 Mln Amendment To Their Collaborationmarkets.businessinsider.com - January 3 at 8:44 AMQ1 2024 Earnings Forecast for Esperion Therapeutics, Inc. Issued By Zacks Research (NASDAQ:ESPR)marketbeat.com - December 22 at 6:52 AMStock Traders Purchase Large Volume of Esperion Therapeutics Call Options (NASDAQ:ESPR)marketbeat.com - December 19 at 10:50 AMEsperion to Participate in 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - December 18 at 10:06 AM Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (Ad)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: Click to get the name of the cryptocurrency ESPR Media Mentions By Week ESPR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ESPR News Sentiment▼0.960.63▲Average Medical News Sentiment ESPR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ESPR Articles This Week▼22▲ESPR Articles Average Week Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SIGA Technologies News Today Precigen News Today Aquestive Therapeutics News Today Larimar Therapeutics News Today Dianthus Therapeutics News Today Entrada Therapeutics News Today Alto Neuroscience News Today Organogenesis News Today Harrow Health News Today ESSA Pharma News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ESPR) was last updated on 3/19/2024 by MarketBeat.com Staff From Our Partners8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.